Evidence map›Paper›PMID 35484216›Full record

ArticleBritish journal of cancer2022

SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling.

Zhongqiu Zhou, Zhuojun Zhang, Han Chen, Wenhao Bao, Xiangqin Kuang, Ping Zhou, Zhiqing Gao, Difeng Li, Xiaoyi Xie, Chunxiao Yang and 8 more

Open access · greenAbstract read
In one paragraph

Article in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. SMK-002 inhibits the growth of bladder cancer cells and increases their sensitivity to OsimertinibThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Enhanced Anti-Lung Cancer Effects of SteamedInternational journal of molecular sciences · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Translational lung cancer research · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Zhongqiu Zhou *Affiliated Cancer Hospital & Institute of Guangzhou Medical University, 510095, Guangzhou, China.
Zhuojun Zhang *Affiliated Cancer Hospital & Institute of Guangzhou Medical University, 510095, Guangzhou, China.
Han Chen *Affiliated Cancer Hospital & Institute of Guangzhou Medical University, 510095, Guangzhou, China.
Wenhao BaoAffiliated Cancer Hospital & Institute of Guangzhou Medical University, 510095, Guangzhou, China.
Xiangqin KuangAffiliated Cancer Hospital & Institute of Guangzhou Medical University, 510095, Guangzhou, China.
Ping ZhouAffiliated Cancer Hospital & Institute of Guangzhou Medical University, 510095, Guangzhou, China.
Zhiqing GaoAffiliated Cancer Hospital & Institute of Guangzhou Medical University, 510095, Guangzhou, China.
Difeng LiAffiliated Cancer Hospital & Institute of Guangzhou Medical University, 510095, Guangzhou, China.
Xiaoyi XieAffiliated Cancer Hospital & Institute of Guangzhou Medical University, 510095, Guangzhou, China.
Chunxiao YangAffiliated Cancer Hospital & Institute of Guangzhou Medical University, 510095, Guangzhou, China.
Xuhong ChenMedical Research Center, Southern University of Science and Technology Hospital, 518055, Shenzhen, China.
Jinyuan PanDepartment of Oncology, Huanggang Central Hospital of Yangtze University, 438000, Huanggang, China.
Ruiming TangThe Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, 511518, Guangzhou, China.
Zhengfu FengThe Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, 511518, Guangzhou, China.
Lihuan ZhouThe Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, 511518, Guangzhou, China.
Lan WangDepartment of Pathogen Biology and Immunology, School of Basic Courses, Guangdong Pharmaceutical University, 510006, Guangzhou, China.
Jianan YangAffiliated Cancer Hospital & Institute of Guangzhou Medical University, 510095, Guangzhou, China. yangjianan@gzhmu.edu.cn.ORCID http://orcid.org/0000-0002-1369-836X
Lili JiangAffiliated Cancer Hospital & Institute of Guangzhou Medical University, 510095, Guangzhou, China. jianglili@gzhmu.edu.cn.ORCID http://orcid.org/0000-0003-2361-5975
Guangzhou Medical University · CNGuangzhou Medical University Cancer Hospital · CNGuangdong Pharmaceutical University · CNMeizhou City People's Hospital · CNSouthern University of Science and Technology · CNYangtze University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with metastatic bladder cancer have very poor prognosis and predictive biomarkers are urgently needed for early clinical detection and intervention. In this study, we evaluate the effect and mechanism of Suprabasin (SBSN) on bladder cancer metastasis.

methodsA tissue array was used to detect SBSN expression by immunohistochemistry. A tumour-bearing mouse model was used for metastasis evaluation in vivo. Transwell and wound-healing assays were used for in vitro evaluation of migration and invasion. Comprehensive molecular screening was achieved by western blotting, immunofluorescence, luciferase reporter assay, and ELISA.

resultsSBSN was found markedly overexpressed in bladder cancer, and indicated poor prognosis of patients. SBSN promoted invasion and metastasis of bladder cancer cells both in vivo and in vitro. The secreted SBSN exhibited identical biological function and regulation in bladder cancer metastasis, and the interaction of secreted SBSN and EGFR could play an essential role in activating the signalling in which SBSN enhanced the phosphorylation of EGFR and SRC kinase, followed with phosphorylation and nuclear location of STAT3.

conclusionsOur findings highlight that SBSN, and secreted SBSN, promote bladder cancer metastasis through activation of EGFR/SRC/STAT3 pathway and identify SBSN as a potential diagnostic and therapeutic target for bladder cancer.

Indexed as

Urinary Bladder NeoplasmsAnimalsAntigens, DifferentiationCell Line, TumorCell MovementErbB ReceptorsGene Expression Regulation, NeoplasticMiceNeoplasm MetastasisPrognosisProto-Oncogene Proteins pp60(c-src)Signal Transductionsrc-Family KinasesAntigens, DifferentiationErbB ReceptorsProto-Oncogene Proteins pp60(c-src)src-Family Kinasessuprabasin protein, mouse

Identifiers

PMID35484216
PMCPMC9296541
OpenAlexW4225009831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.